HIV

This guide is intended to clarify complex testing outcomes and guide laboratory reporting of test results to providers and health department surveillance programs.

This report discusses the estimated HIV incidence and prevalence in the United States 2010–2016.

This report outlines how CDC and its partners are using prevention efforts to reverse the trend of HIV among Hispanic/Latino Gay and Bisexual Men.

This information sheet highlights syphilis and HIV screening practices for pregnant women. The Centers for Disease Control and Prevention (CDC) recommends prenatal testing for syphilis and HIV during a woman’s first prenatal visit and repeat testing for “high-risk” mothers during the third trimester (preferably 28-32 weeks).

Handbook developed by the DC DOH provides guidance on how to advise patients on the benefits of PrEP.

This report summarizes the critical role urbanization practices play in large cities and how they can be used to end the AIDS epidemic by 2030.

AIDSVu offers a variety of ready-made materials and data sets to help illustrate the impact of HIV in the United States. This report presents the state of HIV/AIDS in the United States using 2012 data.

This Vital Signs highlights the importance of expanding access to SSPs, which provide sterile needles and syringes and ideally offer many other comprehensive services to help improve the health of PWID and their communities, such as treatment for substance use disorder, HIV, and hepatitis testing and linkage to treatment, and safe disposal of used syringes.

Video on the development and use of condoms.

This webinar features a presentation from the March 2024 Conference on Retroviruses and Opportunistic Infections (CROI), where Dr. Patrick Sullivan—AIDSVu Principal Scientist and Professor at Emory University—presented the oral abstract, “Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012–2021.” Using real-world data on PrEP coverage, Dr. Sullivan’s study found that states with a higher proportion of people with PrEP indications who were using PrEP experienced steeper declines in new HIV diagnoses over the past decade.